Phagenesis Ltd
Fred Edenius has a strong background in founding and directing companies. Fred is currently the Founder and Director of Scientific Venture Partners (since September 2020) and Ateria Health (since January 2017). Previously, they held the role of Director at Phagenesis Ltd (starting in April 2010) and Anglo Scientific (starting in May 2008 until September 2020). Fred also served as a Director at Apta Biosciences Ltd (from April 2013 to June 2020), Phasor (from March 2018 to April 2020), and Solus Scientific (from July 2009 to May 2019). Fred was a Director at On-Sun Systems from July 2010 to June 2014. Prior to their entrepreneurial ventures, Fred pursued an MBA at London Business School (from September 2006 to July 2008) and participated in the Instep MBA Program at Infosys Technologies Ltd in July 2007.
Fred Edenius has an M.B.A. in Entrepreneurial Management from the London Business School. Additionally, they hold an A.B. degree in Computer Science from Harvard University. However, the specific start and end years for both degrees are not provided.
This person is not in any teams
This person is not in any offices
Phagenesis Ltd
1 followers
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.